Oncology

Lymphatic endothelial cells are found to promote the spread of melanoma

4 May 2018 | By Drug Target Review

Scientists have investigated the mechanisms by which the lymphatic endothelial cells modulate metastasis in melanoma, providing new targets for therapy development.

Taking the brakes off the immune system: modelling effects in non-clinical safety studies

2 May 2018 | By Greg Bannish - Vice President Biopharmaceutical Development Envigo

This article focuses on how the immune system functions, the challenges that it presents to drug development and why there are such concerns around safety that need to be investigated in pre-clinical studies. Moreover, it covers the role of checkpoint inhibitors as an attractive target for cancer immunotherapy.

New insights into the origins of mutations in cancer

2 May 2018 | By Drug Target Review

Scientists use data from human cancers and C. elegans to understand mutational causes of cancer...

Transforming translational research: CANscript^TM – A better predictive model for oncology

27 April 2018 | By Mitra Biotech

In this webinar, speaker Mark Paris, PhD discussed a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript TM;. He also be reviewed the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.

Obesity inhibits key cancer defence mechanism

27 April 2018 | By Drug Target Review

Obesity could enhance cancer development while aspirin might prevent it - a new insight into potential targets for cancer prevention.

Targeting telomerase as therapeutic strategy for melanoma

27 April 2018 | By Drug Target Review

Combination therapy co-targeting the mitochondria enhances the antitumour effect of telomerase inhibition in NRAS-mutant melanoma.

The role of ‘extra’ DNA in cancer evolution and therapy resistance

26 April 2018 | By Drug Target Review

A team of scientists have reported that tumour progression was often driven by cancer-promoting genes, known as oncogenes, on extrachromosomal pieces of DNA.

GLUT5 fluorescent probe fingerprints cancer cells

24 April 2018 | By Drug Target Review

Researchers have explained the basic science behind multicolour probes that enable targeting of cancer-relevant fructose transporter, delving into the image-based detection of cancer cells...

Man-made antibodies show promise in attacking cancer cells in animal models

17 April 2018 | By Dr Zara Kassam (Drug Target Review)

Molecules called aptamers could form new, safer chemotherapy delivery systems...

Contrast-enhanced subharmonic imaging detects prostate cancers

16 April 2018 | By Dr Zara Kassam (Drug Target Review)

A test of contrast-enhanced subharmonic imaging has shown promise in detecting prostate cancers that were not identified by MRI...

New class of drugs could help tackle treatment-resistant cancers

12 April 2018 | By Dr Zara Kassam (Drug Target Review)

Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies...

Mitra Biotech

Study reveals a way to make prostate cancer cells run out of energy and die

6 April 2018 | By Drug Target Review

Scientists have discovered that cells lacking the tumour-suppressor protein PTEN – a feature of many cancers – are particularly vulnerable to drugs that impair their energy-producing mitochondria.

Lymphocytes armed to kill: how customised cell engineering advances immunotherapy

4 April 2018 | By Drug Target Review

The immune system is now regarded as a powerful weapon in the war against cancer, and in the current era immune cells have become ‘living drugs’. This review article considers some of the key advances in immuno-oncology...

Hidden polyps could provide earlier diagnosis of colon cancer

3 April 2018 | By Dr Zara Kassam (Drug Target Review)

New findings may help explain why patients with clean colonoscopies go on to develop colon cancer...